- Home
- LYRA vs BCDA Comparison
LYRA vs BCDA Comparison
Compare LYRA & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- BCDA
- Stock Information
- Founded
- LYRA 2005
- BCDA N/A
- Country
- LYRA United States
- BCDA United States
- Employees
- LYRA N/A
- BCDA N/A
- Industry
- LYRA Medical/Dental Instruments
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- LYRA Health Care
- BCDA Health Care
- Exchange
- LYRA Nasdaq
- BCDA Nasdaq
- Market Cap
- LYRA 11.3M
- BCDA 11.3M
- IPO Year
- LYRA 2020
- BCDA N/A
- Fundamental
- Price
- LYRA $6.37
- BCDA $1.41
- Analyst Decision
- LYRA Hold
- BCDA Strong Buy
- Analyst Count
- LYRA 1
- BCDA 1
- Target Price
- LYRA $16.00
- BCDA $25.00
- AVG Volume (30 Days)
- LYRA 49.1K
- BCDA 300.1K
- Earning Date
- LYRA 11-11-2025
- BCDA 11-12-2025
- Dividend Yield
- LYRA N/A
- BCDA N/A
- EPS Growth
- LYRA N/A
- BCDA N/A
- EPS
- LYRA N/A
- BCDA N/A
- Revenue
- LYRA $770,000.00
- BCDA N/A
- Revenue This Year
- LYRA N/A
- BCDA N/A
- Revenue Next Year
- LYRA $106.28
- BCDA N/A
- P/E Ratio
- LYRA N/A
- BCDA N/A
- Revenue Growth
- LYRA N/A
- BCDA N/A
- 52 Week Low
- LYRA $3.81
- BCDA $1.00
- 52 Week High
- LYRA $37.50
- BCDA $3.20
- Technical
- Relative Strength Index (RSI)
- LYRA 39.68
- BCDA 43.27
- Support Level
- LYRA $6.25
- BCDA $1.35
- Resistance Level
- LYRA $7.30
- BCDA $1.51
- Average True Range (ATR)
- LYRA 0.60
- BCDA 0.10
- MACD
- LYRA -0.13
- BCDA 0.02
- Stochastic Oscillator
- LYRA 8.98
- BCDA 35.71
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).